| Item Type | Name |
|
Concept
|
Administration, Oral
|
|
Concept
|
United States Food and Drug Administration
|
|
Concept
|
Drug Administration Schedule
|
|
Academic Article
|
5-Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for malignant gliomas: a clinical and pharmacologic analysis.
|
|
Academic Article
|
Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender.
|
|
Academic Article
|
Phase I study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762, PNU 152243) administered on a daily x3 schedule.
|
|
Academic Article
|
Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin.
|
|
Academic Article
|
Biochemical and clinical pharmacology of 5-fluorouracil.
|
|
Academic Article
|
Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancer.
|
|
Academic Article
|
Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations.
|
|
Academic Article
|
Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer.
|
|
Academic Article
|
Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
|
|
Academic Article
|
Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma.
|
|
Academic Article
|
End points in cancer clinical trials and the drug approval process.
|
|
Academic Article
|
Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer.
|
|
Academic Article
|
A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer.
|
|
Academic Article
|
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
|
|
Academic Article
|
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
|
|
Academic Article
|
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
|
|
Academic Article
|
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
|
|
Academic Article
|
Oral fluoropyrimidine treatment of colorectal cancer.
|
|
Academic Article
|
Hurry up and wait: is accelerated approval of new cancer drugs in the best interests of cancer patients?
|
|
Academic Article
|
Cytosine arabinoside and cisplatin for advanced breast cancer. A phase II study of the Cancer and Leukemia Group B.
|
|
Academic Article
|
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661.
|
|
Academic Article
|
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
|
|
Academic Article
|
Drug safety and drug efficacy: two sides of the same coin.
|
|
Academic Article
|
Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration.
|
|
Academic Article
|
Personalizing cancer care: American Society of Clinical Oncology presidential address 2009.
|
|
Academic Article
|
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.
|
|
Academic Article
|
Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer.
|
|
Academic Article
|
Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability.
|
|
Academic Article
|
Clinical pharmacology of the stereoisomers of leucovorin during repeated oral dosing.
|
|
Academic Article
|
Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer.
|
|
Academic Article
|
Data submission standards and evidence requirements.
|
|
Academic Article
|
Renal and metabolic toxicities of cancer chemotherapy.
|
|
Academic Article
|
Sequential therapy with dacarbazine and carmustine: a phase I study.
|
|
Academic Article
|
A phase I study of intermittent infusion cladribine in patients with solid tumors.
|
|
Academic Article
|
Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
|
|
Academic Article
|
Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study.
|
|
Academic Article
|
The next phase of chemoprevention research.
|
|
Academic Article
|
The oral fluoropyrimidines in cancer chemotherapy.
|
|
Academic Article
|
Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer.
|
|
Academic Article
|
Phase I study of an oral formulation of ZD9331 administered daily for 28 days.
|
|
Academic Article
|
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
|
|
Academic Article
|
Phase I study of adozelesin administered by 24-hour continuous intravenous infusion.
|
|
Academic Article
|
Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer.
|
|
Academic Article
|
Role of randomized phase III trials in an era of effective targeted therapies.
|
|
Academic Article
|
Sequential administration of methotrexate, cisplatin, and 5-fluorouracil in multimodal therapy for locally advanced head and neck cancer.
|
|
Academic Article
|
Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology.
|
|
Academic Article
|
Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion.
|
|
Academic Article
|
Access versus evidence: The regulators' dilemma.
|
|
Academic Article
|
Hans Christian Andersen and the Value of New Cancer Treatments.
|
|
Academic Article
|
Reevaluating the accelerated approval process for oncology drugs.
|
|
Academic Article
|
Rationale, Opportunities, and Reality of Biosimilar Medications.
|
|
Academic Article
|
Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval.
|
|
Academic Article
|
Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs.
|